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Introduction: QVA149 is a novel, inhaled, once-daily dual bronchodilator containing a fixed-
dose combination of the long-acting b2-agonist indacaterol and the long-acting muscarinic
antagonist glycopyrronium (NVA237), for the treatment of chronic obstructive pulmonary dis-
ease (COPD). This study evaluated the effects of QVA149 on exercise tolerance, hyperinflation,
lung function and lung volumes versus placebo and tiotropium.
Methods: Patients with moderate-to-severe COPD were randomized to QVA149 110/50 mg, pla-
cebo or tiotropium 18 mg once daily in a blinded, 3-period crossover study for 3 weeks. The pri-
mary endpoint was exercise endurance time at Day 21 for QVA149 versus placebo.
Results: Eighty-five patients were randomized; 86% completed the study. QVA149 significantly
improved exercise endurance time at Day 21 compared with placebo (least squares mean
treatment difference 60 s [p Z 0.006]). No significant improvements in exercise endurance
time at Day 21 between QVA149 and tiotropium were found. Dynamic inspiratory capacity
(IC) at exercise isotime, trough forced expiratory volume in 1 s, residual volume and functional
residual capacity showed significant improvements with QVA149 from Day 1 of treatment that
were maintained throughout the study. The safety profiles were similar across groups.iratory Research Institute, Biebricher Allee 34, D-65187 Wiesbaden, Germany. Tel.: þ49 (0) 611
e (K.-M. Beeh).
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improved exercise endurance time compared with placebo which was associated with sus-
tained reductions of lung hyperinflation as indicated by significant improvement in IC at rest
and during exercise.
Trial registration: ClinicalTrials.gov NCT01294787.
Take home message: Dual bronchodilation with QVA149 decreases lung hyperinflation and
improves exercise tolerance and lung function in patients with moderate-to-severe COPD.
ª 2014 The Authors. Published by Elsevier Ltd.Open access under CC BY-NC-ND license.Introduction
Bronchodilators enhance lung emptying by reducing
airway resistance, so patients with COPD are able to
achieve alveolar ventilation at lower operating lung vol-
umes, both at rest and during exercise [1]. As a result,
patients on bronchodilators can exercise longer before
reaching the critical limit of their inspiratory reserve [1].
For symptomatic patients with moderate-to-very severe
COPD, current guidelines recommend treatment with an
inhaled long-acting bronchodilator b2-agonist and/or
muscarinic antagonist or a fixed combination of inhaled
corticosteroid and long-acting bronchodilator in more se-
vere cases [2].
QVA149 is a dual bronchodilator containing a fixed-dose
combination of the long-acting b2-agonist (LABA) indaca-
terol (110 mg) and the long-acting muscarinic antagonist
(LAMA) glycopyrronium (50 mg). In patients with COPD,
QVA149 has demonstrated rapid and sustained bronchodi-
lation, which is statistically significant to that observed
with its monocomponents (indacaterol and glyco-
pyrronium), open-label tiotropium or placebo [3,4], and it
is well tolerated with an adverse event (AE) profile similar
to placebo [5]. Both monocomponents are approved for the
treatment of moderate-to-severe COPD and were found
safe and effective [6e13].
While it is becoming more apparent that dual broncho-
dilation is superior to monotherapy with regards to classical
markers of airflow limitation, the effect of duald, double-blinded (investigator blinded
placebo-controlled, three-pe
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Figure 1 BRIGHTbronchodilation on lung volumes, static and dynamic hy-
perinflation and related outcomes is yet to be established.
The BRIGHT study assessed the impact of QVA149 on exer-
cise endurance and lung function (including dynamic hy-
perinflation) in patients with moderate-to-severe COPD.
The study was designed to compare the effect of QVA149
versus placebo; secondary analyses used tiotropium as an
active treatment comparator as it is a well characterized
standard of care [14,15].
Methods
Study design and treatment
This was a multicenter, randomized, double-blind (investi-
gator-blinded only for tiotropium), double-dummy, pla-
cebo-controlled, three-period, cross-over study (Fig. 1;
Appendix 1).
QVA149 and its placebo were delivered via the
Breezhaler device; tiotropium and its placebo were
delivered via the HandiHaler device. Tiotropium was used
as positive control to assess the assay sensitivity and to
compare the results against a well-known comparator. The
study was powered for comparison of QVA149 and placebo
only. All treatments were given in the morning between
08:00 and 11:00. Short-acting bronchodilators salbutamol
or albuterol were provided for rescue use throughout the
study, however were not permitted within 6 h of each visit
(more details are provided in the online supplement). for tiotropium), double-dummy, multicenter,  
riod, cross-over study
Randomized treatment
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The study population comprised patients 40 years of age
with moderate-to-severe COPD (Stage II or III according to
GOLD 2008 criteria [16]), a smoking history of 10 pack-
years (current or ex-smokers), and a post-bronchodilator
forced expiratory volume in 1 s (FEV1) of 40% and <70%
of the predicted normal, and post-bronchodilator FEV1 to
forced vital capacity (FVC) ratio of <0.70 at screening.
Further details of randomization, and inclusion and exclu-
sion criteria are provided in the online Appendix 1 and 2. All
participants provided written informed consent, and the
study was approved by relevant national and local ethics
review boards.
Endpoints and outcome measures
The primary objective of this study was to compare the
effect of QVA149 with that of placebo on the physiological
responses to exercise during a sub-maximal constant-load
cycle ergometry exercise tolerance test (SMETT) after 3
weeks of treatment. Secondary objectives analyzing
QVA149placebo treatment differences included: isotime
inspiratory capacity (IC) during SMETT, trough IC and trough
FEV1 after 3 weeks of treatment; spirometry measurements
at rest and during SMETT; pulmonary function (via body
plethysmography) after the first dose and after 3 weeks of
treatment (at 5 and 15 min post-dose) and comparison of
the effect of QVA149 and tiotropium on exercise endurance
time. As an important exploratory objective, improvement
in exercise endurance time with tiotropium versus placebo
during SMETT after 3 weeks of treatment was evaluated.
Reduction in rescue medication use and symptoms were
also assessed in patients on QVA149 compared with placebo
via patient diary data.Assessments
Exercise endurance time
Baseline durations of exercise endurance were collected
during wash-out periods (Visits 3, 6 and 9). Patients
commenced load-less pedalling for 3 min at a pedalling
frequency of 60  5 revolutions per minute, followed by
immediate loaded pedalling at 75% of the maximal work-
load (Wmax) that was achieved during a symptom-limited
incremental exercise test performed during screening
[Visit 2]. Time (in seconds) from the start of loaded
pedalling until the point where symptom limitation caused
the patient to stop exercising was recorded (exercise
endurance time), along with the patient’s primary reason
for stopping. This was repeated on Days 1 and 21 of each
treatment period (visits 4, 5, 7, 8, 10 and 11; commencing
75  15 min post-dose).
Spirometry
On Days 1 and 21 of each treatment period (60  15 min
pre-dose) the resting IC, FEV1 and FVC were recorded via
centralized spirometry. Dynamic IC (during patient pedal-
ling) values in duplicate efforts per time-point were
recorded and analyzed pre-exercise (75  15 min post-
dose) at isotime (the latest matching time-point in the
exercise test across all periods at which patients had a valid
test result on Day 1 and Day 21), at peak exercise(immediately prior to patient stopping exercise) and post-
exercise (at 5 min after completion of exercise) and at
trough (60 min pre-dose) on Days 1 and 21 of each treat-
ment period.
Body plethysmography
Constant-volume body plethysmography was performed
60  15 min pre-dose and at 5, 15 and 60  15 min post-
dose on Days 1 and 21 of each treatment period. This
assessed total lung capacity (TLC), expiratory slow vital
capacity (SVC), expiratory reserve volume (ERV), residual
volume (RV), specific airway conductance (SGaw) and
functional residual capacity (FRC).
Patient symptoms and rescue medication use
Patients completed an electronic patient diary twice daily
over the 3-week study period (at the same time each
morning and evening) which recorded morning and evening
daily symptoms (i.e., coughing, wheezing, chest tightness,
ability to clear phlegm/mucus, shortness of breath, fever,
cold, sore throat, and sleep habits) and use of rescue
medication.
Safety
Safety was assessed by physical examination, vital signs,
hematology, clinical chemistry, urinalysis and ECG, as well
as by monitoring all adverse events (AEs).Measures installed for quality assurance
(Appendix-3)
Statistical methods and populations for analysis
The study was formally powered to detect a QVA149-
placebo treatment difference of 105 s in exercise endur-
ance time after 3 weeks of treatment with 90% power.
The primary endpoint was analyzed using a mixed model
for the full analysis set (randomized patients who received
at least one dose of study drug). Further details on the
sample size calculation and statistical methods are given in
the online Appendix 4. The model contained patient
(sequence) as a random effect, and treatment, pre-
treatment exercise period baseline, sequence and period
as fixed effects. The estimated treatment difference
(QVA149placebo) was shown as least squares means (LS
mean), with the associated 95% confidence interval (CI) and
two-sided p-value (significance demonstrated if p < 0.05
and when 95% CI lay entirely to the right of 0 s). Similar
statistical methods were used to analyze the secondary
efficacy endpoints (Appendix 4).Results
Patients
Of the 126 patients screened, 85 patients were randomized
and 73 (85.9%) completed the study (Fig. 2). Patient de-
mographics and other baseline characteristics are shown in
Table 1. Mean age was 62.1 years and the majority of pa-
tients had moderate COPD (72.6%).
Screened (N=126)
Randomized (n=85)
QVA149 (n=77)
Completed (n=73)
Discontinued n=12
• Adverse events n=6
Subject withdrew consent n=3
Administrative reasons n=2
Conditions that no longer 
required treatment n=1
•
•
•
Tiotropium (n=83) Placebo (n=77)
Full analysis data sets for each treatment
Figure 2 Patient disposition.
Of the 12 patients that discontinued, 1 was not exposed to any study medication, 9 received tiotropium, 2 received placebo and
none received QVA149 as the last treatment before discontinuation.
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Exercise endurance time
QVA149 significantly improved exercise endurance time at
Day 21 compared with placebo (primary endpoint; LS meanTable 1 Patient demographics and baseline clinical
characteristics (Safety set).
Total (N Z 84)
Mean (SD) age, years 62.1 (8.11)
Gender, male, n (%) 53 (63.1)
Race, n (%)
Caucasian 81 (96.4)
Other 3 (3.6)
Mean (SD) duration of COPD, years 8.9 (6.81)
COPD severity, n (%)
Moderate 61 (72.6)
Severe 23 (27.4)
ICS use at baseline, n (%) 26 (31.0)
Smoking status, n (%)
Ex-smoker 39 (46.4)
Current smoker 45 (53.6)
COPD exacerbation historya, n (%)
0 70 (83.3)
1 12 (14.3)
2 2 (2.4)
Mean (SD) pre-bronchodilator,
% predicted FEV1
46.5 (10.30)
Mean (SD) post-bronchodilator
FEV1, L
1.6 (0.42)
Mean (SD) post-bronchodilator,
% predicted FEV1
55.9 (8.87)
Mean (SD) post-bronchodilator
FEV1 reversibility, %
22.6 (15.57)
Mean (SD) post-bronchodilator
FEV1/FVC, %
48.5 (9.44)
FEV1 Z forced expiratory volume in 1 s; FVC Z forced vital
capacity; ICS Z inhaled corticosteroid; SD Z standard
deviation.
a In the previous year.treatment difference 60 s (Fig. 3). Although it was an
exploratory objective, a similar magnitude of improvement
was seen for tiotropium compared with placebo (LS mean
treatment difference 66 s (Fig. 3).
At Day 21, in a subgroup of patients with hyperinflation
(FRC >120% predicted), the mean change in exercise
endurance time from baseline for QVA149 (85 s) and tio-
tropium (88 s) was greater compared with placebo (1 s).
These results are similar to those seen in the full analysis
set.
Spirometry
QVA149 treatment significantly improved IC pre-exercise,
at isotime, post-exercise and at trough, compared with
both placebo and tiotropium on Day 21 (Table 2). The dif-
ference between tiotropium and placebo was also signifi-
cant for these measurements, with the exception of IC at
trough (Table 2). A significant improvement was seen in IC
at peak exercise when comparing QVA149 with placebo and
with tiotropium (Table 2).
At Day 21, mean treatment differences in trough IC,
FEV1, and FVC were significantly higher for QVA149 versus400
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Figure 3 Exercise endurance time (seconds) at Day 1 and Day
21 (Full analysis set).
Data are least squares mean  standard error; *p < 0.01.
Table 2 Treatment differences in lung function on Day 21 (Full analysis set).
LS means (95% CI) treatment differences on Day 21
QVA149eplacebo QVA149etiotropium Tiotropiumeplacebo
IC pre-exercise, L 0.34 (0.25, 0.42)*** 0.15 (0.07, 0.23)*** 0.18 (0.10, 0.27)***
IC at isotime, L 0.32 (0.23, 0.40)*** 0.14 (0.05, 0.22)** 0.18 (0.10, 0.27)***
IC at peak exercise, L 0.21 (0.13, 0.30)*** 0.09 (0.00, 0.17)* 0.13 (0.04, 0.21)**
IC post-exercise, L 0.31 (0.20, 0.41)*** 0.18 (0.08, 0.29)*** 0.12 (0.01, 0.23)*
Trough IC, L 0.19 (0.09, 0.29)*** 0.15 (0.06, 0.25)** 0.04 (0.06, 0.13)
Trough FEV1, L 0.20 (0.15, 0.26)*** 0.10 (0.05, 0.15)*** 0.10 (0.05, 0.15)***
Trough FVC, L 0.28 (0.19, 0.37)*** 0.11 (0.02, 0.20)* 0.17 (0.08, 0.27)***
CI Z confidence interval; IC Z inspiratory capacity; FEV1 Z forced expiratory volume in 1 s; FVC Z forced vital capacity.
*p < 0.05; **p < 0.01; ***p < 0.001.
588 K.-M. Beeh et al.placebo (0.19, 0.20 and 0.28 L, respectively) and versus
tiotropium (0.15, 0.10 and 0.11 L, respectively; Table 2).
Body plethysmography
On Days 1 and 21, QVA149 significantly improved FRC, RV,
SVC and SGaw compared with placebo at 5, 15 and
60 min post-dose (Table 3). Tiotropium also produced su-
perior results to placebo, with the exception of RV at
5 min post-dose on Day 1, while QVA149 was superior to
tiotropium for some measurements (in particular SGaw) but
was similar for others (Table 3).
Rescue medication use and patient symptoms
Over the 3-week treatment period, QVA149 resulted in less
rescue mediation use compared to placebo or tiotropium
(mean daily change from baseline: 1.64, 0.42 and 0.42
puffs/day, respectively). QVA149eplacebo adjusted treat-
ment difference was statistically significant (mean differ-
ence in daily use: 1.23; p < 0.001). QVA149etiotropium
adjusted treatment difference was statistically significant
(mean difference in daily use: 1.08; p < 0.001). QVA149
was also superior to placebo for change from baseline in
separate daytime (mean difference 0.81 puffs/day) and
night-time (mean difference 0.44 puffs/day) use of
rescue medication. A greater reduction in mean daily
symptom scores compared to baseline was seen over the 3-
week treatment period for QVA149 (0.64) versus tio-
tropium (0.43) or placebo (0.19).
Exertional dyspnea and leg discomfort in the Borg CR10
scale is given in Table 4. Improvements in exertional dys-
pnea and leg discomfort were not significant with both
QVA149 and tiotropium compared with placebo after 3
weeks treatment.
Safety
The overall incidence of AEs was similar during QVA149
and placebo treatment (37.7% and 36.4%, respectively;
Table 5), and slightly lower during the tiotropium treatment
period (27.7%). No patient discontinued from study drug
due to an adverse event whilst receiving QVA149. Five (6%)
and one (1.3%) patients stopped treatment because of an
AE in the tiotropium and placebo groups, respectively. AEs
reported by at least two patients in any treatment group
are shown in Table 5.
The majority of AEs were mild in severity. Serious
adverse events (SAEs) were reported by one patient foreach treatment, these included colitis (QVA149), acute
myocardial infarction (tiotropium), and pneumonia (pla-
cebo); none were considered to be related to study medi-
cation. There were no deaths reported during the study.Discussion
The BRIGHT study investigated the effect of 3 weeks
treatment with the once-daily dual bronchodilator QVA149
on exercise endurance time and lung function in patients
with moderate-to-severe COPD. The primary objective was
met as QVA149 significantly improved exercise endurance
time versus placebo after 21 days of treatment. The
treatment difference of 60 s for QVA149 is within the clin-
ically meaningful difference proposed by the European
Respiratory Society (ERS) task force on outcomes in
COPD for constant-load endurance tests (46e105 s versus
placebo [17]).
In studies evaluating the effects of bronchodilators on
cycling endurance time in COPD patients, observed results
may vary, with numerically smaller [18,19] or greater
[20,21] effects. Differences in patient populations and
phenotypes, exercise protocols, methodology used for
capturing dynamic IC, and/or study duration make direct
comparisons of treatment effect difficult and complicate
the issue of defining an accepted minimally clinically
important difference for endurance time [22]. Neverthe-
less, the treatment difference seen for tiotropium versus
placebo at Week 3 in this study is comparable to previously
published data [23,18] and a subgroup analysis of patients
in the present study with baseline hyperinflation of FRC
>120% predicted revealed that QVA149 enhanced endur-
ance time after 21 days (þ85 s). Previous studies with its
monocomponents, indacaterol and glycopyrronium showed
a treatment difference of þ87.5 s [24] and þ88.9 s [11],
respectively versus placebo after 3 weeks treatment. In a
recent US Food and Drug Administration (FDA) Pulmonary-
Allergy Drugs Advisory Committee (PADAC) meeting, the
results of two exercise trials also showed that once-daily
LABA olodaterol 5 mg increased cycle ergometry endur-
ance time after 6 weeks by 42e52 s versus placebo [25].
The beneficial effects of QVA149 on endurance time
versus placebo were associated with statistically significant
and clinically important differences in numerous lung
function parameters, including traditional markers of
Table 3 Body plethysmography endpoints (Full analysis set).
LS mean treatment difference (95% CI)
QVA149placebo QVA149tiotropium Tiotropiumplacebo
Day 1 Day 21 Day 1 Day 21 Day 1 Day 21
FRC, L
60 min
pre-dose
0.36***
(0.51, 0.21)
0.11 (0.25, 0.04) 0.26**
(0.40, 0.11)
5 min
post-dose
0.30***
(0.44, 0.16)
0.42***
(0.56, 0.28)
0.10
(0.24, 0.04)
0.08 (0.22, 0.05) 0.20**
(0.34, 0.06)
0.34***
(0.48, 0.20)
15 min
post-dose
0.30***
(0.45, 0.16)
0.41***
(0.56, 0.26)
0.01
(0.15, 0.13)
0.02 (0.17, 0.13) 0.30***
(0.44, 0.15)
0.39***
(0.53, 0.24)
60 min
post-dose
0.35***
(0.50, 0.21)
0.52***
(0.70, 0.35)
0.05
(0.19, 0.10)
0.12 (0.29, 0.06) 0.31***
(0.45, 0.16)
0.40***
(0.58, 0.23)
RV, L
60 min
pre-dose
0.31***
(0.46, 0.16)
0.06 (0.21, 0.08) 0.24**
(0.39, 0.09)
5 min
post-dose
0.28***
(0.41, 0.15)
0.45***
(0.60, 0.30)
0.23***
(0.36, 0.10)
0.11 (0.26, 0.03) 0.05
(0.18, 0.08)
0.34***
(0.48, 0.19)
15 min
post-dose
0.26***
(0.38, 0.14)
0.42***
(0.58, 0.26)
0.03
(0.14, 0.09)
0.05 (0.21, 0.11) 0.23***
(0.35, 0.12)
0.37***
(0.53, 0.21)
60 min
post-dose
0.38***
(0.51, 0.25)
0.52***
(0.70, 0.34)
0.12
(0.25, 0.01)
0.11 (0.28, 0.07) 0.26***
(0.38, 0.13)
0.41***
(0.59, 0.24)
SVC, L
60 min
pre-dose
0.22***
(0.11, 0.32)
0.12* (0.02, 0.23) 0.09
(0.01, 0.20)
5 min
post-dose
0.23***
(0.16, 0.30)
0.29***
(0.19, 0.40)
0.16***
(0.09, 0.23)
0.10* (0, 0.20) 0.08* (0.01, 0.14) 0.19***
(0.09, 0.29)
15 min
post-dose
0.27***
(0.20, 0.33)
0.29***
(0.19, 0.40)
0.11**
(0.05, 0.18)
0.09 (0.01, 0.19) 0.15*** (0.09, 0.22) 0.21***
(0.11, 0.31)
60 min p
ost-dose
0.29***
(0.22, 0.36)
0.35***
(0.25, 0.45)
0.10**
(0.03, 0.17)
0.10 (0, 0.20) 0.18*** (0.11, 0.26) 0.25***
(0.15, 0.35)
SGaw, 1/kP*s
60 min
pre-dose
0.24***
(0.16. 0.31)
0.14*** (0.06, 0.21) 0.10**
(0.03, 0.18)
5 min
post-dose
0.21***
(0.14, 0.29)
0.26***
(0.17, 0.35)
0.13***
(0.06, 0.21)
0.12** (0.03, 0.21) 0.08* (0, 0.15) 0.14**
(0.04, 0.23)
15 min
post-dose
0.22*
(0.04, 0.39)
0.32***
(0.26, 0.38)
0.07
(0.25, 0.10)
0.12*** (0.06, 0.18) 0.29*** (0.12, 0.46) 0.20***
(0.14, 0.26)
60 min
post-dose
0.24***
(0.16, 0.33)
0.37***
(0.30, 0.43)
0.01
(0.07, 0.10)
0.13*** (0.06, 0.19) 0.23*** (0.15, 0.31) 0.24***
(0.18, 0.31)
CIZ confidence interval; FRCZ functional residual capacity; RVZ residual volume; SGawZ specific airway conductance; SVCZ slow
vital capacity.
*p < 0.05; **p < 0.01; ***p < 0.001.
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and airway resistance, as captured by IC and whole-body
plethysmography serial measurements. QVA149 provided
rapid (at 5 and 15 min post-dosing on Day 1) and sustained
(up to Day 21) improvements in lung function, with statis-
tical significance versus placebo and tiotropium. While the
fast onset of action for the single components of QVA149,
indacaterol and glycopyrronium, has been well documented
by standard measures of airflow (FEV1) against both placebo
and active comparators (tiotropium, salmeterol/flutica-
sone) [6,10,13], our study extends these findings to a full
onset of action profile of QVA149 versus placebo on lung
volumes and resistance. While this study was not specif-
ically powered to quantify differences in onset of action
between QVA149 and tiotropium under steady stateconditions, the observed changes in airway conductance
(SGaw) post-dose on Day 21 favoring QVA149 over tio-
tropium indicate that plethysmographic measurement of
airway resistance under non-forced conditions may be a
promising tool to detect pharmacological differences be-
tween bronchodilators‘ in COPD. However, whether these
differences are associated with relevant patient-centered
outcomes, e.g. perception of dyspnea, needs to be evalu-
ated in further studies.
Although, the study was powered to compare the dif-
ferences between QVA149 and placebo only, exploratory
analyses of QVA149 versus tiotropium were also per-
formed. Statistically significant treatment differences
were seen for QVA149 versus tiotropium for several trough
lung function parameters, suggesting superiority of dual
Table 4 Exertional dyspnea and leg discomfort Borg score
at pre-exercise and at isotime after 3 weeks treatment.
LS mean treatment difference (95% CI)
QVA149
placebo
QVA149
tiotropium
Tiotropium
placebo
Exertional dyspnea
Pre-exercise 0.07
(0.20, 0.06)
0.03
(0.09, 0.16)
0.10
(0.23, 0.03)
Isotime 0.10
(0.64, 0.44)
0.19
(0.33, 0.70)
0.29
(0.82, 0.24)
Leg discomfort
Pre-exercise 0.10
(0.25, 0.05)
0.03
(0.18, 0.11)
0.07
(0.21, 0.08)
Isotime 0.10
(0.44, 0.65)
0.04
(0.56, 0.48)
0.14
(0.39, 0.68)
590 K.-M. Beeh et al.versus single bronchodilation as shown elsewhere [3,4],
but these findings were extended by evidence of superior
effects on lung volumes that directly or indirectly
affected lung hyperinflation. Further, the statistical su-
periority of QVA149 versus tiotropium on dynamic IC at
isotime suggests that the documented effects on static
volumes also persisted under exercising conditions. How-
ever, although it has been shown that increases in dy-
namic IC contribute to improvements in endurance time
[26], but no difference in this outcome was seen be-
tween QVA149 and tiotropium. Thus, the superior bron-
chodilation with QVA149 over 21 days on trough lung
function and dynamic IC at isotime did not translate into
superior exercise performance with dual versus single
component bronchodilation. As recent exercise studies
with free or a novel investigational fixed LABA/LAMA
combination also failed to demonstrate superiority of dualTable 5 AEs (by preferred term) reported in 2 patients
with any one treatment.
AE, n (%) QVA149
(N Z 77)
Tiotropium
(N Z 83)
Placebo
(N Z 77)
Any AE 29 (37.7) 23 (27.7) 28 (36.4)
Mild AE 18 (23.4) 12 (14.5) 14 (18.2)
Moderate AE 10 (13.0) 10 (12.0) 11 (14.3)
Severe 1 (1.3) 1 (1.2) 3 (3.9)
COPD
worseninga
7 (9.1) 5 (6.0) 3 (3.9)
Cough 5 (6.5) 0 1 (1.3)
Nasopharyngitis 3 (3.9) 1 (1.2) 3 (3.9)
Sputum
increased
2 (2.6) 0 0
Back pain 1 (1.3) 1 (1.2) 2 (2.6)
Dyspnea 1 (1.3) 2 (2.4) 2 (2.6)
Headache 1 (1.3) 1 (1.2) 2 (2.6)
Contusion 0 2 (2.4) 0
a Data on incidence of COPD exacerbations were combined
with AE data and reported under the preferred term of “COPD
worsening” together with all other events with the same
preferred term.versus single bronchodilation with regard to endurance
time [27], it is worthwhile to discuss possible explanations
for these findings. Firstly, patients in this study (as in
many others) performed their exercise tests at post-dose
and not under trough conditions, so that differences in
bronchodilator effects between the two active regimens
may have been diluted by this approach. However, dif-
ferences in lung volumes favoring QVA149 over tiotropium
were still present post-dose in a magnitude comparable to
trough values, hence it is unlikely that these small nu-
merical changes explain the lacking difference in endur-
ance time.
Secondly, patients in this study represented a popula-
tion not specifically selected for exercise limitation, for
the sake of harmonizing patient populations enrolled in
the QVA149 IGNITE phase III development program [3,28];
therefore, on average, patients had airflow obstruction of
moderate severity (GOLD Stage II). Patients were not
selected on the basis of presence of resting hyperinflation
or respiratory discomfort as their main reason for exercise
limitation. In other studies, the presence of resting hy-
perinflation (FRC>120% predicted) is characteristic of a
patient phenotype with a higher likelihood of dynamic
hyperinflation during activity and exercise limitation due
to respiratory complaints [11,23]. Thus the presence of
other, non-pulmonary factors may have contributed to
exercise limitation in our study. In fact, leg fatigue was
the primary reason for symptom-limited exercise discon-
tinuation with QVA149 (45.5%) and tiotropium (43.8%), but
occurred less frequently with placebo (37.8%), and neither
QVA149 nor tiotropium provided a treatment effect on
Borg dyspnea score during exercise. This may indicate,
that the patient population itself may have reached
‘ceiling effect’ for endurance time achievable by bron-
chodilation, and leads us to believe that extra-pulmonary
limitations such as leg fatigue [29,30] prevented a
distinction of the active treatments based on endurance
time, despite improved bronchodilation with dual versus
single therapy. This is further supported by the fact that
even in those subjects with baseline hyperinflation of FRC
>120% predicted, despite larger overall improvements
versus placebo, a difference between QVA149 and tio-
tropium was not evident. Of interest, in a study comparing
dual (tiotropium plus formoterol) versus single (for-
moterol) bronchodilation, it was shown that patients with
relevant increases in cycling endurance time with dual
over single bronchodilator therapy had more severe
airways obstruction and lower exercise capacity at base-
line [30].
It should be noted that the comparison of endurance
time with QVA149 versus tiotropium was exploratory, and
tiotropium was administered in a single-blinded fashion.
Thus, the lack of an observed difference in our study be-
tween QVA149 and tiotropium does not preclude the pos-
sibility that a difference actually exists, and this could be
explored by studies with extended study duration and/or
patient phenotype with more severe COPD, evidence of
resting (and dynamic) hyperinflation at screening, plus
respiratory symptoms as their primary cause for exercise
limitation. As with other outcomes (exacerbation
[4,31,32]), treatment effects may be better to distinguish
in ‘enriched’ populations, although, it should be noted that
Effect of QVA149 on lung volumes and exercise tolerance 591this approach limits the generalizability of any observed
findings.
A major strength of the present study is its uniqueness in
terms of the measures implemented for coordinated quality
assurance in the methodology used, including, for the first
time, fully centralized capturing and evaluation of serial
dynamic IC manoeuvers, with duplicate measurements for
most time-points. Furthermore, we implemented a thor-
ough quality check for all plethysmographic measurements
with central overread following published recommenda-
tions for determination of lung volumes and resistance,
thus adding external validity to our data. On the other
hand, limitations were present due to patient population as
discussed and study design. The crossover approach, while
permitting recruitment of smaller patients numbers,
thereby minimizing the amount of patients exposed to an
investigational drug, resulted in a large number of exercise
tests (11 per individual); this may have led to a bias in the
results due to a ‘training effect’, although on average, the
comparable endurance times collected at baseline prior to
each 3-week treatment period clearly counter such an
argument.
Conclusions
After 3 weeks of treatment, the once-daily dual broncho-
dilator QVA149 provided a statistically significant and clin-
ically meaningful improvement in markers of
hyperinflation, associated with improved exercise endur-
ance time versus placebo in patients with moderate-to-
severe COPD. Overall, there were no clinically relevant
differences between QVA149 and placebo (or tiotropium)
with respect to safety and tolerability.
Clinical trial
This study is registered at ClinicalTrials.gov with clinical
trial identifier number NCT01294787.
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